Free Trial
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free KLDO Stock Alerts

Kaleido Biosciences (KLDO) Competitors

Kaleido Biosciences logo
$0.0001 0.00 (0.00%)
As of 12:20 PM Eastern
Compare

KLDO vs. PRST, KBNT, AISPW, APCXW, and AUROW

Should you buy Kaleido Biosciences stock or one of its competitors? Kaleido Biosciences's main competitors and comparable companies include Presto Automation (PRST), Kubient (KBNT), Airship AI (AISPW), AppTech Payments (APCXW), and Aurora Innovation (AUROW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Kaleido Biosciences compare to Presto Automation?

Presto Automation (NASDAQ:PRST) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

20.9% of Presto Automation shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 10.0% of Presto Automation shares are held by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Presto Automation has higher revenue and earnings than Kaleido Biosciences. Kaleido Biosciences is trading at a lower price-to-earnings ratio than Presto Automation, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Presto Automation$19.05M0.00-$34.48M-$1.23N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Company Net Margins Return on Equity Return on Assets
Presto AutomationN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

In the previous week, Presto Automation's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Presto Automation Neutral
Kaleido Biosciences Neutral

Presto Automation has a beta of -3.45, indicating that its stock price is 445% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Summary

Presto Automation beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Kubient?

Kubient (NASDAQ:KBNT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Kubient has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kubient$1.17M0.00-$13.62MN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Kubient has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
KubientN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

In the previous week, Kubient's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Kubient Neutral
Kaleido Biosciences Neutral

13.9% of Kubient shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 22.3% of Kubient shares are held by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Kubient beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Airship AI?

Kaleido Biosciences (NASDAQ:KLDO) and Airship AI (NASDAQ:AISPW) are both technology companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Airship AI has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Airship AI$18.15MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Airship AI N/A N/A N/A

In the previous week, Airship AI had 2 more articles in the media than Kaleido Biosciences. MarketBeat recorded 2 mentions for Airship AI and 0 mentions for Kaleido Biosciences. Airship AI's average media sentiment score of 0.94 beat Kaleido Biosciences' score of 0.00 indicating that Airship AI is being referred to more favorably in the news media.

Company Overall Sentiment
Kaleido Biosciences Neutral
Airship AI Positive

81.6% of Kaleido Biosciences shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Airship AI beats Kaleido Biosciences on 3 of the 5 factors compared between the two stocks.

How does Kaleido Biosciences compare to AppTech Payments?

Kaleido Biosciences (NASDAQ:KLDO) and AppTech Payments (NASDAQ:APCXW) are both technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
AppTech Payments N/A N/A N/A

81.6% of Kaleido Biosciences shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled AppTech Payments'average media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
AppTech Payments Neutral

AppTech Payments has lower revenue, but higher earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
AppTech Payments$276KN/AN/AN/AN/A

Summary

Kaleido Biosciences beats AppTech Payments on 3 of the 3 factors compared between the two stocks.

How does Kaleido Biosciences compare to Aurora Innovation?

Aurora Innovation (NASDAQ:AUROW) and Kaleido Biosciences (NASDAQ:KLDO) are both technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

81.6% of Kaleido Biosciences shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Aurora InnovationN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

In the previous week, Aurora Innovation had 3 more articles in the media than Kaleido Biosciences. MarketBeat recorded 3 mentions for Aurora Innovation and 0 mentions for Kaleido Biosciences. Aurora Innovation's average media sentiment score of 0.87 beat Kaleido Biosciences' score of 0.00 indicating that Aurora Innovation is being referred to more favorably in the media.

Company Overall Sentiment
Aurora Innovation Positive
Kaleido Biosciences Neutral

Aurora Innovation has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Innovation$5MN/AN/AN/AN/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Summary

Aurora Innovation beats Kaleido Biosciences on 3 of the 5 factors compared between the two stocks.

Get Kaleido Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLDO vs. The Competition

Export
MetricKaleido BiosciencesSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$4K$16.92B$31.24B$13.18B
Dividend YieldN/A3.42%2.76%19.60%
P/E Ratio0.00111.0562.1018.03
Price / Sales0.001,271.73581.2078.99
Price / CashN/A46.5448.9552.75
Price / BookN/A8.717.725.92
Net IncomeN/A$431.49M$768.63M$380.90M
7 Day PerformanceN/A-2.25%-4.30%-4.38%
1 Month PerformanceN/A-3.17%-3.48%-7.25%
1 Year PerformanceN/A-0.44%163.25%-4.95%

Kaleido Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLDO
Kaleido Biosciences
N/A$0.00
flat		N/A+0.0%$4K$1.10MN/A76
PRST
Presto Automation
N/AN/AN/AN/A$10K$19.05MN/A4
KBNT
Kubient
N/A$0.00
flat		N/A+0.0%$1K$1.17MN/A16
AISPW
Airship AI
N/A$0.53
+9.8%		N/A-74.0%$0.00$18.15MN/A67
APCXW
AppTech Payments
N/A$0.12
flat		N/AN/A$0.00$276KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLDO) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...
Crypto 101 Media | Sponsoredtc pixel
Elon pays this company. Every time.
Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel